| Aug 27 |
RA Capital-backed startup raises $100M; UCB sells China business
|
| Aug 27 |
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
|
| Aug 26 |
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
|
| Aug 26 |
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
|
| Aug 26 |
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
|
| Aug 26 |
2 Unstoppable Stocks That Are Screaming Buys in August
|
| Aug 26 |
J&J plans unilateral reform to 340B drug discount program
|
| Aug 26 |
Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma
|
| Aug 24 |
Is Johnson & Johnson (JNJ) The Best Among The S&P 500 Dividend Aristocrats According to Hedge Funds?
|
| Aug 24 |
Investors in Johnson & Johnson (NYSE:JNJ) have seen notable returns of 46% over the past five years
|
